Lorena Rodríguez-Alonso1, Francisco Rodríguez-Moranta2, Alexandra Ruiz-Cerulla1, Triana Lobatón1, Clàudia Arajol1, Gemma Binefa3, Victor Moreno4, Jordi Guardiola5. 1. Department of Gastroenterology and Hepatology, University Hospital of Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. 2. Department of Gastroenterology and Hepatology, University Hospital of Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Ciber de Epidemiología y Salud Pública (CIBERESP), Spain. 3. Catalan Institute of Oncology, Cancer Prevention and Control Programme, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Ciber de Epidemiología y Salud Pública (CIBERESP), Spain. 4. Catalan Institute of Oncology, Cancer Prevention and Control Programme, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Ciber de Epidemiología y Salud Pública (CIBERESP), Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. 5. Department of Gastroenterology and Hepatology, University Hospital of Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: jguardiola@bellvitgehospital.cat.
Abstract
BACKGROUND: European health systems have developed referral guidelines for the selection of patients for the urgent investigation of suspected colorectal cancer. AIM: To evaluate whether quantitative faecal immunochemical testing performs better than commonly used high-risk symptoms based strategies for fast-tracking cancer referrals. METHODS: We prospectively studied 1054 symptomatic patients referred for a colonoscopy who provided a sample for faecal immunochemical testing. The usefulness of faecal immunochemical testing and two current guidelines for urgent referral were compared for their efficacy in the detection of colorectal cancer and advanced neoplasia. RESULTS: The guidelines detected 46.7% and 43.3% of cases of colorectal cancer while faecal haemoglobin concentration ≥15μg Hb/g detected 96.7% of cases. The diagnostic accuracy of both the guidelines and faecal haemoglobin concentration ≥15μg Hb/g for the detection of advanced neoplasia was: sensitivity 38.3%, 36.1%, 57.1% and specificity 71.8%, 69.5%, 86.6%, respectively. Male gender (OR 2.35; p<0.001), age (1.34; p=0.002), and faecal haemoglobin concentration ≥10μg Hb/g (7.81; p<0.001) were independent predictive factors of advanced neoplasia. CONCLUSIONS: A faecal immunochemical test based-strategy performs better than current high-risk symptoms based strategies for fast-tracking cancer referrals. A score that combines gender, age and a faecal immunochemical test could accurately estimate the risk of advanced neoplasia.
BACKGROUND: European health systems have developed referral guidelines for the selection of patients for the urgent investigation of suspected colorectal cancer. AIM: To evaluate whether quantitative faecal immunochemical testing performs better than commonly used high-risk symptoms based strategies for fast-tracking cancer referrals. METHODS: We prospectively studied 1054 symptomatic patients referred for a colonoscopy who provided a sample for faecal immunochemical testing. The usefulness of faecal immunochemical testing and two current guidelines for urgent referral were compared for their efficacy in the detection of colorectal cancer and advanced neoplasia. RESULTS: The guidelines detected 46.7% and 43.3% of cases of colorectal cancer while faecal haemoglobin concentration ≥15μg Hb/g detected 96.7% of cases. The diagnostic accuracy of both the guidelines and faecal haemoglobin concentration ≥15μg Hb/g for the detection of advanced neoplasia was: sensitivity 38.3%, 36.1%, 57.1% and specificity 71.8%, 69.5%, 86.6%, respectively. Male gender (OR 2.35; p<0.001), age (1.34; p=0.002), and faecal haemoglobin concentration ≥10μg Hb/g (7.81; p<0.001) were independent predictive factors of advanced neoplasia. CONCLUSIONS: A faecal immunochemical test based-strategy performs better than current high-risk symptoms based strategies for fast-tracking cancer referrals. A score that combines gender, age and a faecal immunochemical test could accurately estimate the risk of advanced neoplasia.
Authors: Kevin J Monahan; Michael M Davies; Muti Abulafi; Ayan Banerjea; Brian D Nicholson; Ramesh Arasaradnam; Neil Barker; Sally Benton; Richard Booth; David Burling; Rachel Victoria Carten; Nigel D'Souza; James Edward East; Jos Kleijnen; Michael Machesney; Maria Pettman; Jenny Pipe; Lance Saker; Linda Sharp; James Stephenson; Robert Jc Steele Journal: Gut Date: 2022-07-12 Impact factor: 31.793
Authors: Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca K McCann; Francis A Carey; Callum G Fraser; Robert Jc Steele Journal: Ann Clin Biochem Date: 2021-01-21 Impact factor: 2.057
Authors: Joaquín Cubiella; Pablo Vega; María Salve; Marta Díaz-Ondina; Maria Teresa Alves; Enrique Quintero; Victoria Álvarez-Sánchez; Fernando Fernández-Bañares; Jaume Boadas; Rafel Campo; Luis Bujanda; Joan Clofent; Ángel Ferrandez; Leyanira Torrealba; Virginia Piñol; Daniel Rodríguez-Alcalde; Vicent Hernández; Javier Fernández-Seara Journal: BMC Med Date: 2016-08-31 Impact factor: 8.775
Authors: Alberto Lué; Gonzalo Hijos; Carlos Sostres; Alba Perales; Mercedes Navarro; Maria Victoria Barra; Barbara Mascialino; Carmen Andalucia; Juan José Puente; Ángel Lanas; Fernando Gomollon Journal: Therap Adv Gastroenterol Date: 2020-05-18 Impact factor: 4.409
Authors: Marie Westwood; Shona Lang; Nigel Armstrong; Sietze van Turenhout; Joaquín Cubiella; Lisa Stirk; Isaac Corro Ramos; Marianne Luyendijk; Remziye Zaim; Jos Kleijnen; Callum G Fraser Journal: BMC Med Date: 2017-10-24 Impact factor: 8.775
Authors: Sjoerd G Elias; Liselotte Kok; Niek J de Wit; Ben J M Witteman; Jelle G Goedhard; Mariëlle J L Romberg-Camps; Jean W M Muris; Karel G M Moons Journal: BMC Med Date: 2016-09-26 Impact factor: 8.775